Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors
- PMID: 29606147
- PMCID: PMC5880088
- DOI: 10.1186/s12967-018-1452-4
Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors
Abstract
Background: Immune checkpoint inhibitors (anti-CTLA-4, anti-PD-1, or the combination) enhance anti-tumor immune responses, yielding durable clinical benefit in several cancer types, including melanoma. However, a subset of patients experience immune-related adverse events (irAEs), which can be severe and result in treatment termination. To date, no biomarker exists that can predict development of irAEs.
Methods: We hypothesized that pre-treatment antibody profiles identify a subset of patients who possess a sub-clinical autoimmune phenotype that predisposes them to develop severe irAEs following immune system disinhibition. Using a HuProt human proteome array, we profiled baseline antibody levels in sera from melanoma patients treated with anti-CTLA-4, anti-PD-1, or the combination, and used support vector machine models to identify pre-treatment antibody signatures that predict irAE development.
Results: We identified distinct pre-treatment serum antibody profiles associated with severe irAEs for each therapy group. Support vector machine classifier models identified antibody signatures that could effectively discriminate between toxicity groups with > 90% accuracy, sensitivity, and specificity. Pathway analyses revealed significant enrichment of antibody targets associated with immunity/autoimmunity, including TNFα signaling, toll-like receptor signaling and microRNA biogenesis.
Conclusions: Our results provide the first evidence supporting a predisposition to develop severe irAEs upon immune system disinhibition, which requires further independent validation in a clinical trial setting.
Keywords: Antibodies; Biomarker; Immunotherapy; Melanoma; Toxicity.
Figures
Similar articles
-
A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab.J Immunother Cancer. 2018 Sep 18;6(1):90. doi: 10.1186/s40425-018-0408-9. J Immunother Cancer. 2018. PMID: 30227886 Free PMC article.
-
Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors.Oncologist. 2017 Oct;22(10):1232-1237. doi: 10.1634/theoncologist.2017-0133. Epub 2017 Jun 26. Oncologist. 2017. PMID: 28652280 Free PMC article.
-
Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.Oncologist. 2016 Oct;21(10):1230-1240. doi: 10.1634/theoncologist.2016-0055. Epub 2016 Jul 8. Oncologist. 2016. PMID: 27401894 Free PMC article. Review.
-
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Clin Ther. 2015. PMID: 25823918 Free PMC article. Review.
-
Role of mass spectrometry-based serum proteomics signatures in predicting clinical outcomes and toxicity in patients with cancer treated with immunotherapy.J Immunother Cancer. 2022 Mar;10(3):e003566. doi: 10.1136/jitc-2021-003566. J Immunother Cancer. 2022. PMID: 35347071 Free PMC article. Review.
Cited by
-
Non-bacterial cystitis caused by pembrolizumab therapy for adenocarcinoma of the lung: a case report.Front Immunol. 2024 Jul 5;15:1423123. doi: 10.3389/fimmu.2024.1423123. eCollection 2024. Front Immunol. 2024. PMID: 39034999 Free PMC article.
-
Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma.J Immunother Cancer. 2024 Jun 30;12(6):e009215. doi: 10.1136/jitc-2024-009215. J Immunother Cancer. 2024. PMID: 38945553 Free PMC article.
-
Distinct autoantibody profiles across checkpoint inhibitor types and toxicities.Oncoimmunology. 2024 May 9;13(1):2351255. doi: 10.1080/2162402X.2024.2351255. eCollection 2024. Oncoimmunology. 2024. PMID: 38737792 Free PMC article. Clinical Trial.
-
Unraveling the complex interplay between anti-tumor immune response and autoimmunity mediated by B cells and autoantibodies in the era of anti-checkpoint monoclonal antibody therapies.Front Immunol. 2024 Jan 22;15:1343020. doi: 10.3389/fimmu.2024.1343020. eCollection 2024. Front Immunol. 2024. PMID: 38318190 Free PMC article. Review.
-
T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy.J Immunother Cancer. 2023 Aug;11(8):e007236. doi: 10.1136/jitc-2023-007236. J Immunother Cancer. 2023. PMID: 37604642 Free PMC article.
References
-
- Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016;17(11):1558–1568. doi: 10.1016/S1470-2045(16)30366-7. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical